Galectin Therapeutics Inc. announced that the company has recently expanded its management team with multiple key leadership appointments, including Dakshina Reddy, MSM, as Executive Director, Regulatory Affairs; Ezra R. Lowe, Ph.D., as Executive Director, Clinical and Preclinical Pharmacology; Marla Mills-Wilson as Executive Director, Clinical Operations; and Jessica Kopaczewski as Associate Director, Clinical Operations. These strategic appointments strengthen the company’s clinical, regulatory, and operational efforts across its ongoing programs in cancer immunotherapy and NASH cirrhosis. Dakshina Reddy most recently worked for Novartis as Global Program Regulatory Director, where he led and achieved successful approvals of IND’s, NDA’s, sNDA’s and MAA’s in the U.S., E.U., Japan, China, Brazil and Mexico. Ezra R. Lowe, Ph.D. Prior to joining Galectin, Ezra was Senior Director, Clinical Pharmacology in Global R&D with the Bausch Health Companies.